SOURCE: Cannabis Therapy Corp.

Cannabis Therapy Corp.

August 12, 2014 09:00 ET

Cannabis Therapy Corp. Moves to Leverage Pet Health Sector and Offers Details on New Product Lineup

Company Initiates Plans Aimed at Growth of Hemp-Based Pet Therapy Operations

BOULDER, CO--(Marketwired - Aug 12, 2014) - Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"), a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, ultra-low THC, cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is pleased to offer additional information regarding its Canna-Pet™ product mix, and subsequent plans for upcoming marketing activities to support the recently announced worldwide and exclusive licensing of the entire Canna-Pet™ brand and animal health operation.

Canna-Pet™ ( products are all available over-the-counter, without a prescription or authorization. Originally available exclusively in capsule form (in varying doses), Canna-Pet™ introduced Canna-Biscuits™ treats for dogs in April, and the Company aims to make Canna-Pet Max CBD available as a nutraceutical additive for pet foods in late 2014. Canna-Pet™ products are recommended as a daily oral food additive for all pets, but especially for those with inflammation, allergies, anxiety or behavior issues, compromised immune systems, digestive issues, nausea, chronic pain, cancer, seizures, and palliative care.

The entire Canna-Pet™ product line is currently produced in the Seattle area within specialized facilities utilizing proprietary production methods. The manufacturing processes are consistent with Cannabis Therapy's mission to launch pharmaceutical grade, hemp-based products and the end result is a line of quality animal oriented medications devoid of psychoactivity. Canna-Pet™ products are recommended by over 200 DVMs (Doctors of Veterinary Medicine) in the USA and Canada, and to-date Canna-Pet™ has helped over 1,000,000 pets and earlier this year celebrated the production milestone of over 10 million capsules.

Cannabis Therapy Corp. has begun the development of a marketing plan, targeting key market segments, to boost the current monthly revenue generated by the sales of Canna-Pet™ products. To date, the products are sold exclusively through online, web-based sales and referrals, and new branding opportunities, including future product and business development outreach efforts to both DVMs and consumers are being studied by Cannabis Therapy Corp. The analysis will lead to subsequent implementation of appropriate and proven marketing strategies later in the year. Based on statistics for the pet sector alone, the Company aims to address a tactical mix of consumer and industry advertising along with key conferences and trade exhibitions to stimulate vertical and channel distribution opportunities.

The Pet industry in the United States is massive and growing. Statistics from the American Pet Products Association ( show that in 2013, $55.72 billion was spent on pets in the U.S. and projections currently estimate a total $58.51 billion for 2014 broken down as follows:

Food: $22.62 billion
Supplies/OTC Medicine: $13.72 billion
Vet Care: $15.25 billion
Live animal purchases: $ 2.19 billion
Pet Services: grooming & boarding: $ 4.73 billion

Many of the categories above could play a role in developing channel markets for functional CBD-based products derived from legally obtained and pharmaceutically processed industrial Hemp. In fact, the possibility for even a single blockbuster product in this all-new segment of the Animal Health sector could prove game changing.

Cannabis Therapy Corp. President & CEO Dr. Soren Mogelsvang comments, "The 'natural health' sub segment of the Animal Health sector appears to be the fastest growing specialty area in the industry today. We aim to move quickly to position Canna-Pet™ into a leading, trusted brand based on outstanding science, rigorous quality assurance and a commitment to proven pharmaceutical industry production standards. The opportunity to develop this operating arm of Cannabis Therapy Corp. is exciting and fast-moving. We look forward to a very busy year ahead as we continue to build value through the development of both human and animal health therapies in our growing company."

For more information about the Company please visit and watch our corporate video at

Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at For more information please visit

About Cannabis Therapy Corp. (OTCQB: CTCO)
Cannabis Therapy Corp. aims to develop and market safe, phytocannabinoid-based medicinal products and to apply rigorous manufacturing and quality control standards to become a global leader in the research, development, manufacturing, testing and marketing of cannabinoid ingredients and therapies for both humans and animals. For more information visit

About Canna-Pet™ Products for Pet Health
Developed in a collaboration between Doctors of Veterinary Medicine in six states and an MIT entrepreneur, Canna-Pet products are the culmination of twenty years of research and development in cannabinoid therapies for animals. Canna-Pet, LLC currently produces the only veterinarian recommended, legal, over the counter CBD products for animals, made from industrial hemp and manufactured in the USA. Canna-Pet™ products are offered as capsules in four dosages, and as Canna-Biscuits™ treats. All products contain not only CBD, but other cannabinoids and terpenes (essential oils) that make Canna-Pet™ products uniquely effective. Canna-Pet™ products are available worldwide, under an exclusive license agreement with Cannabis Therapy Corp. (OTCQB: CTCO). For more information visit:

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; and the Company's business, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended to diagnose, treat, cure, or prevent any disease.


Soren Mogelsvang, President & CEO
Cannabis Therapy Corp.

Contact Information